Femme Homme
- | Pays :
- Bosnia and Herzegovina
- | Organes : -
- | Spécialités : -
Extrait
This single arm, open label study will assess the efficacy and safety of and compliance to treatment with Bonviva/Boniva (ibandronate) in biphosphonate-naïve patients with post-menopausal osteoporosis. Patients will receive Bonviva/Boniva at a dose of 3 mg intravenously every three months. Anticipated time on study treatment is 12 months with a follow-up of 12 months.
Critère d'inclusion
- Post Menopausal Osteoporosis